ALK and non-small cell lung carcinoma: Currently, atezolizumab in combination with carboplatin plus nab-paclitaxel or with bevacizumab, carboplatin, and paclitaxel have been officially approved as a first-line treatment for metastatic non-squamous NSCLC lacking EGFR mutation or ALK rearrangements, based on the OS benefit over their comparator chemotherapy alone (5, 6).